If you liked this article you might like

Pharma Has History of Price Gouging, Mylan Should Be No Surprise
Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble
Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation
Gilead May Be Better Off Splitting Itself in Two, Analysts Say